+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.

Age: 18Years +All GendersPhase 2
109 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of combination antibiotic therapy compared to single antibiotic therapy for adults hospitalized with Staphylococcus aureus bloodstream infections. This study focuses on patients identified as high-risk early in their infection and aims to determine if combination therapy improves outcomes compared to monotherapy. Both methicillin-sensitive and methicillin-resistant bacterial infections are included. The trial is a randomized, crossover Phase 4 study conducted in hospitals. Participants with methicillin-sensitive Staphylococcus aureus bacteremia MSSAB will receive either a single intravenous beta-lactam antibiotic cefazolin or nafcillin or combination therapy including that beta-lactam plus ertapenem. Those with methicillin-resistant Staphylococcus aureus bacteremia MRSAB will be treated with either monotherapy of vancomycin or daptomycin or combination therapy with daptomycin plus ceftaroline. Treatment assignments alternate monthly by hospital. Low-risk patients receive usual care without randomization. During the study, participants will be monitored from enrollment through 30 and 90 days for various outcomes including a desirability of outcome ranking, hospital-free days alive, mortality rates, bacteremia-free days, hospital length of stay, direct hospital costs, antibiotic costs, antibiotic-associated adverse events, and Clostridioides difficile infections. Data from all hospitalized patients with SAB at participating hospitals will be analyzed. The study is expected to complete in January 2029.

Age: 18Years +All GendersPhase 4
13 locations